List view / Grid view
23 June 2015 | By Victoria White
Data presented at ASCO 2015 suggests that the Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape...
11 June 2015 | By Victoria White
The global market value for axial spondyloarthritis therapeutics will expand from $1.5 billion in 2014 to reach $2.9 billion by 2024...
10 June 2015 | By Victoria White
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets...
9 June 2015 | By Victoria White
Cost-containment measures are shifting the decision-making focus of North America’s pharmaceutical market from the prescriber to the payer, says GlobalData...
27 May 2015 | By Victoria White
The global market value for advanced wound dressings will increase to reach $3.51 billion by 202, according to research and consulting firm GlobalData...
21 May 2015 | By Victoria White
Despite optimism surrounding new dengue and a malaria vaccines, vaccination alone is not a long-term solution for combatting these diseases, says GlobalData...
20 May 2015 | By Victoria White
The global treatment market for dyslipidemia will more than double from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, according to GlobalData...
13 May 2015 | By Victoria White
The treatment market value for fibromyalgia across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting…
7 May 2015 | By Victoria White
The global market for Alzheimer’s disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023...
30 April 2015 | By Victoria White
Genocea's GEN-003 is better positioned to compete in the future genital herpes treatment space, despite being slightly behind Agenus’ HerpV in development...
30 April 2015 | By Victoria White
The market value for prostate cancer will expand more than threefold to an estimated $8.2 billion by 2023, driven by the label extension of Xtandi...
24 April 2015 | By Victoria White
The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, says leading research and consulting firm GlobalData.
16 April 2015 | By Victoria White
The melanoma treatment market will increase from $1.34 billion in 2013 to $5.64 billion by 2023, representing a robust CAGR of 15.5%, reports GlobalData...
15 April 2015 | By Victoria White
The global treatment market for Duchenne Muscular Dystrophy will expand in value at a CAGR of 160.5% to $990 million by 2019, says GlobalData...
7 April 2015 | By Victoria White
The combined total revenues for the peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014, representing a Compound Annual Growth Rate (CAGR) of 21.9%, according to research and consulting firm GlobalData.
